This phase I trial is designed to evaluate the safety and maximum tolerated dose (MTD) of a new oral drug, given in combination with a type of immunotherapy in patients with solid cancersA Phase 1, Open-label, Multicenter, Safety Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies

Exclusion

• Predicted life expectancy <3 months.
• Primary central nervous system (CNS) tumors.
• Symptomatic or impending cord compression. Stable CNS disease is allowed.
• History of cerebrovascular stroke or transient ischemic attack within previous 6 months.
• Prior solid organ or hematologic transplant.
• History or current retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vascular occlusion (RVO), neovascular macular degeneration.
• Any clinically significant cardiac disease.
• Active, known or suspected autoimmune disease.
• History of or current interstitial lung disease or pneumonitis.
• Receipt of a live-virus vaccination within 28 days, viral vaccine that do not contain live virus within 7 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
• Known infection with human immunodeficiency virus (HIV), known uncontrolled hepatitis B infection, active tuberculosis, or severe infection requiring parenteral antibiotic treatment.
• Inadequate hematologic, hepatic and renal function.
• Known second malignancy.
• Impairment of gastrointestinal function.
• Any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol.
• History of severe allergic reaction to any of the study intervention components.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.